This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duh, M. S. Articles by Waltzman, R. J. Search for Related Content PubMed PubMed Citation Articles by Duh, M. S. Articles by Waltzman, R. J.

Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve

^a Analysis Group, Inc., Boston, Massachusetts, USA; ^b Groupe d’Analyse, Ltée., Montréal, Canada; ^c Ortho Biotech Clinical Affairs, LLC, Bridgewater, New Jersey, USA; ^d St. Vincent’s Comprehensive Cancer Center, New York, New York, USA

Correspondence: Correspondence: Mei Sheng Duh, M.P.H., Sc.D., Analysis Group, Inc., 111 Huntington Avenue, Tenth Floor, Boston, Massachusetts 02199, USA. Telephone: 617-425-8131; Fax: 617-425-8001; e-mail: mduh{at}analysisgroup.com

Introduction. In assessing erythropoietic agents for chemotherapy-induced anemia, traditional single time–point end points (e.g., hematopoietic response [HR]) fail to reflect clinical benefits over the entire therapy course. Area under the hemoglobin change curve (Hb AUC) is introduced as an alternative measure, and its reliability, clinical significance, and superiority are assessed.

Methods. Using data from a phase IV open-label epoetin alfa (EPO) trial, we tested Hb AUC reliability by comparing its values derived from primary patient data with those derived from aggregated data. Clinical significance of the Hb AUC was investigated in three phase IV EPO trials by examining the linear relationship between Hb AUC quartiles and established clinical end points. The superiority of the Hb AUC over HR in its association with blood transfusion was tested through logistic regressions and area under the receiver operating characteristic (ROC) curve analysis.

Results. The Hb AUC values derived from patient and aggregated data were similar. Strong and statistically significant linear trends of decreasing transfusion requirements, increasing quality-of-life improvements, and decreasing time to HR were found across Hb AUC quartiles. The Hb AUC rendered the HR variable insignificant when both were present in the same model. Area under the ROC curve analysis supported the superior performance of the Hb AUC.

Conclusions. We found that the Hb AUC is an objective, reliable, clinically meaningful, and comprehensive summary statistic that may be used to quantify clinical benefits for patients receiving erythropoietic agents. Further prospective validation of the Hb AUC metric is recommended.

Key Words. Anemia • Area under the curve • erythropoietin • chemotherapy-induced anemia

This article has been cited by other articles:

				P. Pedrazzoli, A. Farris, S. Del Prete, F. Del Gaizo, D. Ferrari, C. Bianchessi, G. Colucci, A. Desogus, T. Gamucci, A. Pappalardo, et al. Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa J. Clin. Oncol., April 1, 2008; 26(10): 1619 - 1625. [Abstract] [Full Text] [PDF]

				P. Cremieux, F. Vekeman, and P. Lefebvre Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application Journal of Oncology Pharmacy Practice, September 1, 2006; 12(3): 165 - 178. [Abstract] [PDF]